JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Reproductive dysfunction in women with epilepsy: menstrual cycle abnormalities, fertility, and polycystic ovary syndrome.

Epilepsy can be associated with reproductive endocrine disorders. In women these include polycystic ovary syndrome (PCOS), isolated components of this syndrome such as polycystic ovaries or hyperandrogenemia, hypothalamic amenorrhea (HA), or functional hyperprolactinemia (HPRL). The most likely explanations for endocrine disorders related to epilepsy are a direct influence on the endocrine control centers in the brain (the hypothalamic-pituitary axis) or are effects of antiepileptic drugs (AEDs) on peripheral endocrine glands. Furthermore, the effects of AEDs on the metabolism of hormones and binding proteins and secondary endocrine complications of AED-related weight changes or changes of insulin sensitivity must be considered. Therefore, regular monitoring of reproductive function at visits, including questioning about menstrual disorders, fertility, weight, hirsutism and galactorrhea are recommended. Single abnormal laboratory or imaging findings without symptoms may not constitute a clinically relevant endocrine disorder. However, patients with these kinds of abnormalities should be monitored in order to detect the possible development of a symptomatic disorder associated with, for example, menstrual disorders or fertility problems. If a reproductive endocrine disorder is subsequently found, AEDs should be reviewed in terms of their indication for the particular seizure type and their tolerability vis-à-vis their potential for contributing to the endocrine problem.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app